Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Updated results from an ongoing trial
- 30 April 2006
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 54 (4) , S154-S163
- https://doi.org/10.1016/j.jaad.2005.12.018
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trialJournal of the American Academy of Dermatology, 2005
- Ciclosporin in psoriasis clinical practice: an international consensus statementBritish Journal of Dermatology, 2004
- Efalizumab for Patients With Moderate to Severe Plaque PsoriasisJAMA, 2003
- A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque PsoriasisNew England Journal of Medicine, 2003
- Therapeutic strategies for psoriasisJournal of Clinical Pharmacy & Therapeutics, 2000
- Systemic sequential therapy of psoriasis: A new paradigm for improved therapeutic resultsJournal of the American Academy of Dermatology, 1999
- Cyclosporine consensus conference: With emphasis on the treatment of psoriasisJournal of the American Academy of Dermatology, 1998
- Methotrexate in psoriasis: Consensus conferenceJournal of the American Academy of Dermatology, 1998
- An approach to the treatment of moderate to severe psoriasis with rotational therapyJournal of the American Academy of Dermatology, 1993
- The Natural History of Psoriasis in 5,600 PatientsDermatology, 1974